{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:10:26Z","timestamp":1779919826966,"version":"3.53.1"},"reference-count":37,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016047","name":"Science Fund of the Republic of Serbia","doi-asserted-by":"publisher","award":["6777"],"award-info":[{"award-number":["6777"]}],"id":[{"id":"10.13039\/501100016047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Vedolizumab is a gut-selective anti-integrin monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). While clinical trials have demonstrated a favorable safety profile, real-world studies are essential for identifying rare adverse events (AEs) and evaluating post-marketing safety. This study assessed vedolizumab\u2019s safety in a real-world cohort and supported the detection of potential safety signals. Methods: A retrospective chart review was conducted on adult IBD patients treated with vedolizumab at a tertiary center in the Republic of Serbia between October 2021 and August 2022. Data included demographics, AEs, and newly reported extraintestinal manifestations (EIMs). Exposure-adjusted incidence rates were calculated per 100 patient-years (PYs). Disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) was performed to identify safety signals, employing reporting odds ratios (RORs) and proportional reporting ratios (PRRs) for AEs also observed in the cohort. Prior IBD therapies and reasons for discontinuation were evaluated. Results: A total of 107 patients (42.1% Crohn\u2019s disease, 57.9% ulcerative colitis) were included, with a median vedolizumab exposure of 605 days. There were 92 AEs (56.51\/100 PYs), most frequently infections (23.95\/100 PYs), gastrointestinal disorders (4.30\/100 PYs), and skin disorders (4.30\/100 PYs). The most frequently reported preferred terms (PTs) included COVID-19, COVID-19 pneumonia, nephrolithiasis, and nasopharyngitis. Arthralgia (12.90\/100 PYs) was the most frequent newly reported EIM. No discontinuations due to vedolizumab AEs occurred. FAERS analysis revealed potential signals for events not listed in prescribing information but observed in the cohort: nephrolithiasis, abdominal pain, diarrhea, malaise, cholangitis, gastrointestinal infection, blood pressure decreased, weight decreased, female genital tract fistula, respiratory symptom, and appendicectomy. Most patients had received three prior therapies, often stopping one due to AEs. Conclusions: Vedolizumab demonstrated a favorable safety profile in the IBD cohort. However, FAERS-identified signals, such as nephrolithiasis, gastrointestinal infections, and decreased blood pressure, warrant further investigation in larger, more diverse populations.<\/jats:p>","DOI":"10.3390\/ph18081127","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T07:57:24Z","timestamp":1753689444000},"page":"1127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Bojana","family":"Mila\u0161inovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-2145","authenticated-orcid":false,"given":"Sandra","family":"Vezmar Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-5704","authenticated-orcid":false,"given":"Sr\u0111an","family":"Markovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Medical Center \u201cZvezdara\u201d, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-7509","authenticated-orcid":false,"given":"Marija","family":"Jovanovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Kne\u017eevi\u0107 Ivanovski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Medical Center \u201cZvezdara\u201d, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9153-2153","authenticated-orcid":false,"given":"\u0110or\u0111e","family":"Kralj","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Medical Center \u201cZvezdara\u201d, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-812X","authenticated-orcid":false,"given":"Petar","family":"Svorcan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Medical Center \u201cZvezdara\u201d, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-5976","authenticated-orcid":false,"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-5785","authenticated-orcid":false,"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of inflammatory bowel disease: A comprehensive review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3892\/etm.2023.11997","article-title":"Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Tang","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., Lees, C., Louis, E., Luk\u00e1\u0161, M., and Reinisch, W. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02347-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14740338.2015.1063612","article-title":"Safety of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"14","author":"Hagan","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"(2025, May 14). Entyvio FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/entyvio.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apt.16060","article-title":"Long-term safety of vedolizumab for inflammatory bowel disease","volume":"52","author":"Loftus","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and crohn\u2019s disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ecco-jcc\/jjad043","article-title":"Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies","volume":"17","author":"Macaluso","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/ecco-jcc\/jjy047","article-title":"Respiratory tract infections in patients with inflammatory bowel disease: Safety analyses from vedolizumab clinical trials","volume":"12","author":"Feagan","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Marafini, I., Troncone, E., Rocchetti, I., and Monteleone, G. (2020). Respiratory tract infections in inflammatory bowel disease patients taking vedolizumab: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.585732"},{"key":"ref_20","unstructured":"Takeda Pharmaceuticals U.S.A. Inc. (2025, May 14). ENTYVIO (Vedolizumab) Injection, for Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761359s000lbl.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Alameddine, Z., Abi Melhem, R., Dimachkie, R., Rabah, H., Chehab, H., El Khoury, M., Qaqish, F., Stefanov, D., and El-Sayegh, S. (2023). Risk of nephrolithiasis in patients with inflammatory bowel disease receiving biologic treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196114"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.15171\/jnp.2017.42","article-title":"Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis","volume":"6","author":"Nasri","year":"2017","journal-title":"J. Nephropathol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yang, L., and Yuan, L. (2024). Investigating the causal relationship between inflammatory bowel disease and simple appendicitis using Mendelian randomization. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-74572-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: The safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/apt.15538","article-title":"Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data","volume":"51","author":"Card","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apt.14459","article-title":"Postoperative outcomes in vedolizumab-treated Crohn\u2019s disease patients undergoing major abdominal operations","volume":"47","author":"Lightner","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5217\/ir.2020.00117","article-title":"Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study","volume":"20","author":"Poylin","year":"2022","journal-title":"Intest. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Markovi\u0107, S., Kralj, \u0110., Svorcan, P., Kne\u017eevi\u0107 Ivanovski, T., Odanovi\u0107, O., Obradovi\u0107, S., Hom\u0161ek, A., Jovanovi\u0107, M., Savi\u0107, R., and Vu\u010di\u0107evi\u0107, K.M. (2024). Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16121629"},{"key":"ref_31","unstructured":"U.S. Food and Drug Administration (2012). Guidance for Industry and Investigators, Safety Reporting Requirements for INDs and BA\/BE Studies."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","article-title":"Efficacy and safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease patients stratified by age","volume":"34","author":"Yajnik","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_33","unstructured":"(2024, December 27). Medical Dictionary for Regulatory Activities. Available online: https:\/\/www.ich.org\/page\/meddra."},{"key":"ref_34","unstructured":"(2024, December 24). FDA\u2019s Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers."},{"key":"ref_35","unstructured":"(2025, May 14). OpenVigil 2.1, OpenVigil\u2014A Pharmacovigilance Data Analysis Tool. Available online: https:\/\/openvigil.sourceforge.net."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:06Z","timestamp":1760033826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/8\/1127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ph18081127"],"URL":"https:\/\/doi.org\/10.3390\/ph18081127","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}